AGP Picks
View all

HepaGam B market seen growing on hepatitis B burden and prevention demand

Nov. 4, 2026
HepaGam B market seen growing on hepatitis B burden and prevention demand
By AI, Created 14:15 UTC, Nov 04, 2026, AGP -

The Business Research Company says the HepaGam B market will expand through 2035 as hepatitis B cases, hospital prophylaxis use and public health campaigns drive demand. North America is expected to stay the largest region in 2025, while Asia-Pacific is forecast to grow fastest.

Why it matters: - HepaGam B is used to help prevent hepatitis B infection after exposure, making it relevant for healthcare workers, newborns of infected mothers and other high-risk patients. - Rising global hepatitis B cases are keeping pressure on prevention and post-exposure treatment markets. - The market outlook matters for hospitals, public health systems and immunoglobulin suppliers as countries push hepatitis elimination goals.

What happened: - The Business Research Company published a report titled The HepaGam B Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035. - The report says the HepaGam B market is being shaped by hepatitis B prevalence, immune globulin use, hospital adoption for exposure risks and gaps in vaccination programs. - The company says future growth will be supported by stronger public health policies, better safety measures for healthcare workers, expanded screening, more hospital-based prophylaxis and hepatitis elimination campaigns. - The report identifies demand for post-exposure prophylaxis, maternal and neonatal protection, wider immunoglobulin use, greater prevention awareness and infection control improvements as key trends. - The company offers a free sample of the report. - The company also offers the full market report.

The details: - HepaGam B is a human hepatitis B immune globulin designed to provide passive immunity through antibodies targeting hepatitis B surface antigens. - The product is typically administered by injection. - HepaGam B is part of post-exposure prophylaxis protocols aimed at reducing infection risk after possible exposure. - The report says rising hepatitis B infections remain a major growth driver. - Hepatitis B can lead to chronic liver disease, cirrhosis and liver cancer. - The report links higher HBV incidence to insufficient vaccination coverage, higher transmission among vulnerable groups and low awareness of prevention. - The World Health Organization said in April 2024 that about 254 million people were living with chronic hepatitis B in 2022. - The World Health Organization also said there were about 1.2 million new cases annually and nearly 1.1 million deaths, mostly from cirrhosis and hepatocellular carcinoma. - The report says rising healthcare spending should also lift demand for HepaGam B by widening access to preventive treatments and immunoglobulin therapy. - The World Health Organization said in April 2024 that global health initiatives aim to ensure 80% of people with chronic hepatitis B and C receive treatment by 2030. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report says North America is projected to remain the largest market region for HepaGam B in 2025. - The report says Asia-Pacific is expected to grow the fastest during the forecast period. - The 2026 report format includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables.

Between the lines: - The report points to a market shaped less by routine use and more by exposure-driven prevention, which tends to rise when screening, maternal protection and infection control become policy priorities. - The combination of high disease burden and public health targets suggests demand could stay tied to broader hepatitis elimination efforts rather than short-term product cycles. - Regional growth differences imply mature markets like North America may lead in size, while Asia-Pacific may offer the strongest expansion opportunity.

What's next: - The market outlook through 2035 will likely track hepatitis B prevalence, vaccination coverage, screening activity and hospital prophylaxis adoption. - Public health policies and treatment access goals could further support demand if countries move toward elimination targets. - The company’s report suggests future updates will focus on trend analysis, forecasting tools and regional opportunities. - Contact details for the report are included in the release for buyers seeking more information.

The bottom line: - HepaGam B demand is being fueled by persistent hepatitis B burden and the need for rapid post-exposure prevention, with North America leading in size and Asia-Pacific leading in growth potential.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

One World Daily Brief

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

One World Daily Brief

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.